曲奥舒凡在造血干细胞移植预处理中的药代动力学与变异性
本文首次全面综述曲奥舒凡及其活性环氧化物的药代动力学,聚焦造血干细胞移植预处理。文章分析分布容积和总清除率在婴儿、1岁以上儿童和成人中的个体间变异及可能协变量,描述S,S-EBDM和S,S-DEB的形成速率限制性消除及前药暴露与S,S-EBDM的相关性,并讨论消除半衰期对预处理成功的意义及未来治疗药物监测前景。
要点
- 曲奥舒凡最佳剂量尚未确定,尤其在婴儿中。
- 前药暴露与S,S-EBDM在儿童中的暴露存在相关性。
- S,S-EBDM和S,S-DEB的消除受形成速率限制。
核心结论
- 曲奥舒凡的药代动力学及其变异性在婴儿、儿童和成人中存在差异,最佳剂量尤其婴儿尚未解决。
- 前药暴露与S,S-EBDM在儿童中的相关性及消除半衰期对预处理成功有重要意义。
研究设计与样本
- 综述首次全面回顾曲奥舒凡及其生物活性环氧化物的药代动力学,聚焦HSCT预处理。
- 数据主要来自近3年研究,讨论分布容积和总清除率及其协变量。
主要发现
- 分析了婴儿、1岁以上儿童和成人中分布容积和总清除率的个体间变异及可能协变量。
- 描述了S,S-EBDM和S,S-DEB的形成速率限制性消除,包括儿童中前药暴露与S,S-EBDM的相关性。
- 讨论了大鼠中曲奥舒凡和S,S-EBDM的器官处置与临床毒性及清髓活性的关系。
临床怎么用
- 综述旨在帮助药师和医生理解曲奥舒凡的临床药代动力学。
- 提出了未来治疗药物监测的展望。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treosulfan is a prodrug that undergoes a highly pH- and temperature-dependent nonenzymatic conversion to the monoepoxide {(2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate [S,S-EBDM]} and diepoxide {(2S,3S)-1,2:3,4-diepoxybutane [S,S-DEB]}. Currently, treosulfan is tested in clinical trials as an alternative to busulfan in conditioning prior to hematopoietic stem cell transplantation (HSCT). Of note, the optimal dosing of the prodrug is still unresolved, especially in infants. In this paper, the pharmacokinetics of treosulfan, together with its biologically active epoxides, is comprehensively reviewed for the first time, with the focus on conditioning prior to HSCT. Most of the insightful data presented in this review comes from studies that have been conducted in the last 3 years. The article widely discusses the volume of distribution and total clearance of treosulfan. In particular, the interindividual variability of these key parameters in infants, children above 1 year of age, and adults is analyzed, including possible covariates. A clinically important aspect of the formation rate-limited elimination of S,S-EBDM and S,S-DEB is described, including the correlation between the exposure of the prodrug and S,S-EBDM in children. The significance of the elimination half-life of treosulfan and its epoxides for successful conditioning prior to HSCT is also raised. Furthermore, the organ disposition of treosulfan and S,S-EBDM in rats is discussed in the context of the clinical toxicity and myeloablative activity of treosulfan versus busulfan. Moreover, perspectives for future therapeutic drug monitoring of treosulfan are presented. The review is intended to be helpful to pharmacists and doctors in the comprehension of the clinical pharmacokinetics of treosulfan.
引用
- Romański M, Wachowiak J, Główka FK, et al. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives. Clin Pharmacokinet. 2018. PMID: 29557088. doi:10.1007/s40262-018-0647-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。